Veterinary Medicines

Ultifend ND IBD (--) - Concentrate and solvent for suspension for injection

Authorised
  • Turkey herpesvirus, strain rHVT/ND/IBD (cell-associated), expressing fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus, Live
Download as PDF

Product identification

Medicine name:
Ultifend ND IBD (--) - Concentrate and solvent for suspension for injection
Active substance:
  • Turkey herpesvirus, strain rHVT/ND/IBD (cell-associated), expressing fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus, Live
Target species:
  • Chicken
  • Chicken (embryonated eggs)
Route of administration:
  • In ovo
  • Subcutaneous use

Product details

Active substance and strength:
  • Turkey herpesvirus, strain rHVT/ND/IBD (cell-associated), expressing fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus, Live
    Presentation_strength:4000 PFU/dose - 12000 PFU/dose Index:0
Pharmaceutical form:
  • Concentrate and solvent for suspension for injection
Withdrawal period by route of administration:
  • In ovo
    • Chicken
      • Not applicable
        0
        day
  • Subcutaneous use
    • Chicken
      • Not applicable
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD16
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Package description:
  • Packaging:Concentrate: ampoule (glass), solvent: bag (PVC), Package_size:1 ampoule, Content:2000 doses
  • Packaging:Concentrate: ampoule (glass), solvent: bag (PVC), Package_size:1 ampoule, Content:1000 doses
  • Packaging:Concentrate: ampoule (glass), solvent: bag (PVC), Package_size:1 ampoule, Content:4000 doses

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Ceva-Phylaxia Co. Ltd
Marketing authorisation date:
Manufacturing sites for batch release:
  • Ceva-Phylaxia Zrt.
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 22/11/2022
Download
Bulgarian (PDF)
Published on: 22/11/2022
Download
Croatian (PDF)
Published on: 22/11/2022
Download
Czech (PDF)
Published on: 22/11/2022
Download
Danish (PDF)
Published on: 22/11/2022
Download
Dutch (PDF)
Published on: 22/11/2022
Download
Estonian (PDF)
Published on: 22/11/2022
Download
Finnish (PDF)
Published on: 22/11/2022
Download
French (PDF)
Published on: 22/11/2022
Download
German (PDF)
Published on: 22/11/2022
Download
Greek (PDF)
Published on: 22/11/2022
Download
Hungarian (PDF)
Published on: 22/11/2022
Download
Icelandic (PDF)
Published on: 22/11/2022
Download
Italian (PDF)
Published on: 22/11/2022
Download
Latvian (PDF)
Published on: 22/11/2022
Download
Lithuanian (PDF)
Published on: 22/11/2022
Download
Maltese (PDF)
Published on: 22/11/2022
Download
Norwegian (PDF)
Published on: 22/11/2022
Download
Polish (PDF)
Published on: 22/11/2022
Download
Portuguese (PDF)
Published on: 22/11/2022
Download
Romanian (PDF)
Published on: 22/11/2022
Download
Slovak (PDF)
Published on: 22/11/2022
Download
Slovenian (PDF)
Published on: 22/11/2022
Download
Spanish (PDF)
Published on: 22/11/2022
Download
Swedish (PDF)
Published on: 22/11/2022
Download